Thymogen

Thymogen is a synthetic dipeptide composed of L-glutamic acid and L-tryptophan (L-Glu-L-Trp, EW, molecular weight 333.34 g/mol, CAS 38101-59-6). It was isolated by Vladimir Khavinson and Vyacheslav Morozov via reverse-phase high performance liquid chromatography fractionation of Thymalin, the calf thymus polypeptide preparation, in the late 1980s. The dipeptide was identified as the principal active component of Thymalin and shown to reproduce the immunomodulatory activity of the crude thymic extract. Thymogen was registered as a pharmaceutical drug in the USSR in 1990 under Russian Ministry of Health Registration Certificate No. P N002408/01 (renewed June 10, 2009). The compound is available in Russia and CIS countries in three approved formulations: intramuscular injection (100 mcg per ampoule), intranasal spray, and topical cream. Indications in Russian clinical practice include post-operative immune recovery, chronic infectious diseases, oncology adjuvant settings, pediatric immunodeficiency, and adjunctive use in burns and trauma. The compound has no FDA, EMA, or MHRA approval.

Isolation from Thymalin

The Khavinson program in the 1970s and 1980s focused on identifying the active components within tissue-derived polypeptide preparations (cytomedins) that could be synthesized as simpler defined compounds (cytogens). Thymalin, the calf thymus preparation registered in 1982, was the starting point for this fractionation work.

The isolation methodology involved reverse-phase high performance liquid chromatography fractionation of Thymalin, screening of isolated peptide fractions for immunomodulatory activity using the active E-rosette test (which assesses T-lymphocyte detection after trypsin treatment), structure-activity relationship studies of synthetic isomers and analogs, and identification of Glu-Trp as the principal active dipeptide.

Subsequent SAR studies of synthetic Glu-Trp family peptides identified related active compounds. The Glu-Trp dipeptide itself was registered as Thymogen in 1990.

The Three Approved Formulations

Russia approved Thymogen in three formulations, an unusually flexible regulatory framework:

Intramuscular injection: 100 mcg per ampoule, the most commonly used clinical formulation. Used in adult immunodeficiency, post-operative recovery, severe infections.

Intranasal spray: convenient pediatric and outpatient formulation. Used for respiratory and ENT immune support, particularly in children with recurrent respiratory infections.

Topical cream: used for wound healing, dermatological conditions with immune components, and adjunctive treatment of skin infections.

Documented Pharmacology

The Khavinson group and Russian collaborators have documented several pharmacological effects of Thymogen. Immune effects include T-cell differentiation activation, T-cell recognition of peptide-MHC complexes, normalization of CD4/CD8 ratios, enhancement of neutrophilic chemotaxis and phagocytosis, NK cell function modulation, and cytokine production effects. Intracellular signaling effects include changes in intracellular cyclic nucleotide composition.

Anti-carcinogenic effects have been documented including reduced spontaneous tumor incidence in rats (Anisimov 2000), inhibitory effect on chemical carcinogenesis (esophagus and forestomach tumors induced by N-nitrososarcosine ethyl ester), and effects on radiation-induced carcinogenesis.

Geroprotective effects: the Anisimov 2000 Biogerontology paper reported that L-Glu-L-Trp slows aging in rats. Female rats receiving subcutaneous Thymogen showed extended lifespan compared to saline-injected controls, with reduced incidence of spontaneous mammary tumors and other age-related neoplasms.

L-Form vs D-Form Activity

An interesting mechanistic feature of Thymogen is the differential activity between the L-form (the active immunostimulant) and the D-form. Some research has reported that the D-form may have immunosuppressant rather than immunostimulant activity, raising mechanistic questions that remain incompletely resolved. The pharmaceutical preparation uses only the L-form.

Russian Clinical Use Patterns

Documented Russian clinical applications of Thymogen include adult immunodeficiency and secondary immune deficiencies, post-operative immune recovery, chronic infectious diseases (recurrent respiratory infections, chronic bronchitis, tuberculosis), pediatric recurrent respiratory infections (intranasal spray), burns and trauma (parenteral and topical), oncology adjuvant, type 1 diabetes mellitus (some Russian protocols), adjunctive treatment in chronic dermatological conditions (topical), and post-radiation immune recovery.

Comparison with Thymalin

The relationship between Thymogen (dipeptide) and Thymalin (parent polypeptide complex) is conceptually important. Thymalin is a complex mixture containing multiple bioactive thymic peptides with manufacturing involving tissue extraction from bovine sources. Thymogen is a defined single molecule with manufacturing involving chemical synthesis. Reproducibility is higher. The two compounds are both approved in Russia and have overlapping but not identical clinical applications.

Western Research Gap

Despite the substantial Russian pharmaceutical history, Thymogen has minimal Western research attention: no Phase 1, 2, or 3 trials registered with FDA or EMA, no peer-reviewed Western RCT publications, limited coverage in mainstream Western immunology journals, and not included in standard Western immunology guidelines.

Regulatory Status

• Russia: Approved as pharmaceutical drug since 1990 (Registration Certificate No. P N002408/01, renewed June 2009)
• CIS countries: Approved in multiple Commonwealth of Independent States
• FDA: Not approved
• EMA: Not approved
• WADA: Not currently on the prohibited list

Thymogen's mechanism is incompletely characterized in Western pharmacological terms but has been studied in Russian preclinical work.

Proposed Epigenetic Mechanism

The Khavinson framework proposes that Thymogen acts through direct interaction with DNA and histones in immune cells. The dipeptide is claimed to penetrate immune cell membranes, enter the nucleus, interact with DNA or chromatin, and modulate gene expression in immune-related genes. Direct structural biology confirmation of specific DNA binding has not been published.

Documented Cellular Effects

Independent of the proposed mechanism, several effects have been documented:

T-cell effects: Thymogen treatment increases T-lymphocyte counts in patients with reduced baseline values, particularly the helper-inducer (CD4) subpopulation. The CD4/CD8 ratio normalizes in patients with abnormal baseline ratios.

Macrophage and neutrophil effects: enhanced phagocytic activity and neutrophilic chemotaxis.

Cyclic nucleotide effects: changes in intracellular cAMP and cGMP, which are second messengers involved in immune cell activation and regulation.

MHC class effects: enhanced T-cell recognition of peptide-MHC complexes, suggesting effects on antigen presentation and T-cell receptor engagement.

Alternative Mechanistic Interpretations

For a dipeptide, several mechanisms could potentially contribute to observed effects:

Free amino acid effects: rapid peptide hydrolysis releases glutamic acid and tryptophan. Tryptophan is a precursor for serotonin, kynurenine pathway metabolites, and other immunologically active compounds.

PepT1 transporter mediated absorption: dipeptides are recognized by intestinal PepT1 transporters.

Receptor-mediated effects: immune cell-surface receptors could potentially bind the dipeptide.

Cyclic dipeptide formation: Glu-Trp can spontaneously cyclize to form cyclo(Glu-Trp), a diketopiperazine. Cyclic dipeptides have documented bioactive properties.

Pharmacokinetics

The pharmacokinetics of Thymogen are not well-characterized by Western standards. Intramuscular and subcutaneous administration provides rapid absorption with very short plasma half-life (minutes) due to peptidase activity. Intranasal administration provides direct local delivery to respiratory mucosa with some systemic absorption.

Effects in Russian clinical practice and published Russian literature:

• Restoration of immune parameters in adult and pediatric immunodeficiency
• Reduced frequency of recurrent respiratory infections (particularly in children with intranasal spray)
• Post-operative immune recovery support
• Adjunctive benefits in chronic infectious diseases
• Wound healing acceleration (topical formulation)
• Oncology adjuvant: supportive role alongside conventional treatment
• Post-radiation immune restoration
• Subjective well-being improvements
• Combination effects with Thymalin and other Khavinson preparations

Effects in animal studies (Khavinson and Anisimov laboratories):

• Lifespan extension in rats (Anisimov 2000)
• Reduced spontaneous tumor incidence in aged rats
• Inhibition of chemical carcinogenesis (esophageal and forestomach tumors)
• Inhibition of radiation-induced carcinogenesis
• Enhanced T-cell differentiation
• Improved phagocytosis and neutrophilic chemotaxis
• Effects on cyclic nucleotide composition

Effects in Western peer-reviewed clinical trials: none rigorously published.

Honest evidence framing: Thymogen has a substantial Russian preclinical and clinical evidence base spanning more than 35 years of pharmaceutical use. The Anisimov 2000 Biogerontology paper documenting lifespan extension and reduced spontaneous carcinogenesis in rats is the most cited preclinical finding. Russian clinical research documents broad immunomodulatory effects across multiple indications, supported by three approved formulations covering injectable, nasal, and topical routes. The principal limitations are absence of Western Phase 3 clinical trials, methodological differences from Western RCT standards, variable quality control between Russian pharmaceutical-grade and international research-chemical sources, and incomplete pharmacokinetic characterization.

Important note: Thymogen has Russian regulatory approval and established Russian clinical protocols across three formulations. There is no FDA-approved dosing protocol.

Standard Russian clinical protocols by formulation:

Intramuscular injection:

• 100 mcg (0.1 mg) once daily
• Course duration: 3-10 days
• Cycle frequency: every 3-6 months
• Supplied as 100 mcg ampoules

Intranasal spray:

• 1-2 sprays in each nostril
• 1-2 times daily
• Course duration: 3-10 days
• Often used for respiratory immune support in children

Topical cream:

• Applied to affected skin areas
• Frequency depends on condition

Off-label international protocols (often differ from Russian clinical doses):

• 1-5 mg subcutaneously per injection (much higher than Russian clinical dose)
• Cycles of 10 days

Stacking considerations within the Khavinson framework:

• Thymogen + Thymalin: synthetic dipeptide cytogen + parent natural cytomedin
• Thymogen + Epitalon: combined thymic and pineal anti-aging
• Thymogen + Cortexin: combined immune and neurological support
• Thymogen + Bronchogen or Chonluten: combined respiratory-immune support

Special populations:

• Pregnancy: avoid. No adequate safety data
• Breastfeeding: avoid
• Pediatric: Russian intranasal spray approved for pediatric use in specific indications
• Active autoimmune flare: theoretical caution
• Solid organ transplant recipients: avoid due to potential immune restoration interfering with immunosuppression
• Hematological malignancies: theoretical caution

Adverse effects reported in Russian-language literature and 35+ years of clinical use:

• Generally well-tolerated
• Local injection site reactions (occasional)
• Rare allergic reactions
• Mild nasal irritation with intranasal spray (occasional)
• Mild headache (occasional)
• No serious adverse events consistently reported

Theoretical concerns:

• Autoimmune exacerbation: as an immunomodulator, Thymogen could theoretically worsen autoimmune conditions
• Transplant rejection: solid organ transplant recipients on immunosuppression could theoretically experience reduced graft tolerance
• Hematological effects: theoretical concerns in patients with hematological malignancies
• Long-term safety in Western populations: not independently characterized at Western trial standards
• Quality control variability: practical concern between Russian pharmaceutical-grade and international suppliers
• D-form versus L-form: only the L-form is the active immunostimulant. The D-form has different activity
• Drug interactions: not systematically studied
• Cyclic dipeptide formation: storage conditions may allow formation of cyclo(Glu-Trp), with potentially different activity profile

Contraindications and cautions:

• Pregnancy and breastfeeding
• Hypersensitivity to the peptide
• Active autoimmune flare (relative caution)
• Solid organ transplant recipients
• Active hematological malignancy (theoretical caution)
• Severe acute infection requiring immediate antimicrobial therapy (not a substitute)

Drug interactions: theoretical interactions with immunosuppressants (calcineurin inhibitors, mTOR inhibitors, antimetabolites, corticosteroids) and checkpoint inhibitor immunotherapy. Combinations with other Khavinson preparations are standard in Russian protocols.

Pregnancy, breastfeeding: avoid.

Pediatric: Russian intranasal spray approved for specific pediatric indications.

Athletes: Thymogen is not currently on the WADA prohibited list (as of 2026).

Thymogen is the synthetic dipeptide cytogen counterpart to the natural cytomedin Thymalin within the Khavinson framework. Its closest companions:

• Thymalin: the parent natural polypeptide complex from calf thymus from which Thymogen was isolated as the principal active dipeptide via HPLC fractionation
• Vilon: a different Khavinson dipeptide (Lys-Glu) also targeting thymic and immune function. Different sequence from Thymogen but similar conceptual framing
• Epitalon: Khavinson pineal tetrapeptide (AEDG). The most-studied Khavinson peptide internationally. Often combined with Thymogen for combined thymic-pineal anti-aging effects
• Cortexin: Khavinson brain cortex polypeptide preparation. Often combined with Thymogen in elderly patients

Common combinations within the Khavinson framework:

• Thymogen + Thymalin: synthetic dipeptide plus parent polypeptide complex in sequential or combined administration
• Thymogen + Epitalon: combined thymic-pineal axis for anti-aging
• Thymogen + Cortexin: combined immune and neurological support in elderly
• Thymogen intranasal + Bronchogen: combined nasal and bronchial immune support for respiratory protection
• Thymogen topical + wound care: topical formulation for dermatological adjuvant use

Combinations to approach with caution:

• Immunosuppressants (cyclosporine, tacrolimus, mycophenolate, azathioprine): theoretical interference with immunosuppression
• Checkpoint inhibitor immunotherapy (pembrolizumab, nivolumab, ipilimumab): theoretical immune modulation effects unknown
• Active autoimmune flare: relative caution
• Solid organ transplant recipients: avoid
• Active hematological malignancy: theoretical caution
• Pregnancy and breastfeeding: avoid

The most actionable framing of Thymogen in 2026: this is a Khavinson synthetic dipeptide cytogen (L-Glu-L-Trp, EW) isolated as the principal active component of Thymalin via HPLC fractionation, registered as a Russian pharmaceutical since 1990 in three formulations (intramuscular, intranasal, topical). The compound has a substantial Russian clinical and preclinical evidence base spanning more than 35 years, with notable animal data including the Anisimov 2000 Biogerontology paper reporting lifespan extension and reduced spontaneous carcinogenesis in rats. Russian clinical use spans adult and pediatric immunodeficiency, post-operative recovery, chronic infections, oncology adjuvant, and dermatological applications. Western peer-reviewed Phase 3 clinical trials are absent. The proposed mechanism (direct peptide-DNA interaction) remains debated by Western molecular biology standards, though alternative mechanisms (free amino acid effects, receptor-mediated effects, cyclic dipeptide formation) could contribute to documented activity. Quality control varies between Russian pharmaceutical-grade and international research-chemical sources. For patients on immunosuppression for transplant or autoimmune disease, Thymogen should be avoided. For evidence-based immune support, vaccination programs and treatment of underlying conditions have stronger Western evidence bases.

For informational and educational purposes only. Not medical advice. Not for human consumption unless prescribed by a licensed physician for an FDA-approved indication. Consult a qualified healthcare provider before using any peptide or pharmaceutical product.